Search Results

ZAP-X Gyroscopic Stereotactic Radiosurgery Platform Makes Its Australian Debut, Expanding Precision Non-Invasive Brain Radiotherapy

ZAP Surgical, the global leader in non-invasive robotic brain surgery, recently announced that GenesisCare will become the first cancer care provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery platform. Installation of the device is scheduled to begin this month at the GenesisCare center located at St Vincent's Hospital Sydney in New South Wales, with the first patients expected to receive treatment before the end of this year. The introduction of the ZAP-X platform will significantly enhance GenesisCare's neuro-oncology diagnostic and treatment capabilities in Sydney, providing it with dedicated stereotactic radiosurgery (SRS) services. Prior to this, patients receiving S...

2026-09-17

IAEA's Rays of Hope Initiative Boosts Global Cancer Care

The IAEA's Rays of Hope initiative aims to expand access to cancer care, drive innovation, and build partnerships to narrow the global gap in cancer treatment. Every year, cancer claims more than 10 million lives, and that number is expected to nearly double by 2050. While many cancers are treatable, especially when detected early, timely diagnosis and life-saving treatment are unevenly distributed around the world. Low- and middle-income countries often lack modern medical imaging and radiotherapy equipment, trained oncologists, research capacity, and basic services. More than half of cancer cases occur in these countries, and nearly two-thirds...

2026-09-16

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Promotes the Translation and Application of Medical X-ray Skin Protective Agent

On September 10, Zhang Jianhong, Party Secretary of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, led a delegation to Nanjing to conduct research with the Institute of Dermatology, Chinese Academy of Medical Sciences and Jiangsu Haizhi Biomedical Co., Ltd., exchanging views on the translation and application of the medical X-ray skin protective agent project. Representatives from the hospital, research institute, and enterprise held discussions on industry-university-research collaboration, clinical demand alignment, and industrialization pathways. It is understood that the medical X-ray skin protective agent is one of the core products in the radiation protection series independently developed by the Institute of Radiation Medicine. After being put into production, the product is expected to become China's first medical X-ray skin protective agent for scar radiotherapy. At the symposium, Zhang Jianhong stated that dermatology...

2026-09-12

Rapid Arc Dynamic Precision Radiotherapy Technology Launched in Western New South Wales, Australia

Cancer patients in western New South Wales, Australia, have recently gained a new radiotherapy option. The Western New South Wales Local Health District has introduced Rapid Arc Dynamic (RAD) technology at the Western Cancer Centre at Dubbo Health Service, becoming the first public health institution in Australia to offer this service. According to reports, RAD is a highly precise and personalized radiotherapy technology that can help clinicians more accurately target tumor areas while minimizing radiation exposure to surrounding healthy tissue. This technology is suitable for a variety of treatment scenarios, particularly for patients with longer tumor extents and lymph node metastases. R...

2026-09-10

Alpha-9 Oncology Initiates Phase 1 Clinical Trial of GRPR-Targeted Radiotherapy, First Patient Dosed

Alpha-9 Oncology, a U.S. clinical-stage radiopharmaceutical company, recently announced that the first patient has been dosed in its Phase 1 clinical trial evaluating two GRPR-targeted radiopharmaceuticals. The study involves the actinium-225-labeled compound 225Ac-A9-0642 and the lutetium-177-labeled compound 177Lu-A9-0631, primarily enrolling patients with breast cancer and other solid tumors, with data expected to be released by the end of 2027. According to the company, both 225Ac-A9-0642 and 177Lu-A9-0631 target the gastrin-releasing peptide receptor (GRPR). GRPR is considered a solid tumor-associated target with potential clinical value in breast cancer and other solid tumors. 225Ac-A9-0642 is Alpha-9's first actinium-225 GRPR-targeted compound to enter clinical evaluation...

2026-09-09

Cancer Hospital of the First Hospital of Jilin University Established, Granted Configuration Permit for Heavy Ion Radiotherapy System

Recently, the 7th Bethune Conference on New Advances in Cancer Treatment was held in Changchun, Jilin Province. The conference coincided with the 80th anniversary of Jilin University and the 20th anniversary of the Cancer Center of the First Hospital of Jilin University, aiming to establish a high-level academic exchange platform and promote the continuous improvement of cancer diagnosis and treatment capabilities in the three northeastern provinces. During the conference, the inauguration ceremony of the Cancer Hospital of the First Hospital of Jilin University was also held. According to reports, the newly established Cancer Hospital will, based on the coordinated development of the original Cancer Center, integrate three advantageous disciplines—oncology, hematology, and radiation oncology—further improve the multidisciplinary collaborative diagnosis and treatment model, promote smoother connections in cancer diagnosis and treatment processes, and enhance comprehensive treatment capabilities for difficult cancers. The conference also...

2026-09-08

IAEA 70th General Conference to Host Technical Cooperation Side Events Focusing on Radiotherapy Financing and African Nuclear Workforce Development

The 70th Regular Session of the International Atomic Energy Agency General Conference will be held from September 14 to 18, 2026, at the Vienna International Centre in Austria. During the session, delegates and technical experts from various countries will discuss the Agency's ongoing work and topics related to nuclear science and technology. The 70th Regular Session of the IAEA General Conference will take place from September 14 to 18, 2026, at the Vienna International Centre. (IAEA) As part of the arrangements related to the General Conference, the IAEA Department of Technical Cooperation will host two side events during the conference week, highlighting its technical cooperation support to Member States. One event will focus on financing for the expansion of radiotherapy services, while the other will...

2026-09-03

FDA Grants Breakthrough Therapy Designation to JBS-003 for Guiding De-escalated Radiotherapy in HPV-Positive Oropharyngeal Cancer

On September 1, Juniper Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its hypoxia tracer JBS-003. The product, 18F-Fluoromisonidazole (FMISO), is intended to identify tumor hypoxia and guide de-escalated radiotherapy in patients with HPV-positive oropharyngeal cancer (OPC). JBS-003 is licensed from Memorial Sloan Kettering Cancer Center (MSK). According to information released by the company, the tracer is based on F-MISO PET molecular imaging technology and can visualize specific hypoxic features within tumors. Tumor hypoxia is considered to be associated with radioresistance; by imaging hypoxic regions, clinicians can stratify patients by risk and...

2026-09-02

Assam, India, Plans to Introduce Proton Beam Therapy for Cancer Treatment at a Public Hospital

Cancer treatment capabilities in Assam, India, are set to be upgraded. Assam Chief Minister Himanta Biswa Sarma announced that the state cabinet has approved the introduction of a proton beam therapy system at Gauhati Medical College Hospital. Once the project is completed, Assam will become the third region in India to offer proton beam therapy, and the hospital will be the first public hospital in India to be equipped with this technology. Currently, proton beam therapy is already in use at the Tata Memorial Centre in Mumbai and the Apollo Proton Cancer Centre in Chennai. The facility planned at Gauhati Medical College Hospital will become the third such treatment center in India. Proton beam therapy is an advanced form of radiotherapy used to treat cancer and certain non-cancerous tumors. Unlike conventional radiation therapy, which typically uses X-rays, proton therapy delivers precise irradiation to the tumor area using high-energy positively charged particles—protons. As proton beams enter the body, they release energy, causing DNA damage to cells. Healthy cells generally possess some capacity for repair, whereas cancer cells are less able to repair themselves, thereby inhibiting their growth and proliferation and helping to destroy tumor tissue.

2026-08-31

Construction of Radiotherapy Room at Sao San Tun Hospital in Taunggyi, Myanmar, Approximately 80% Complete

On August 30, 2026, the Chief Minister of Shan State, Myanmar, U Sai Tin Soe, accompanied by relevant officials, inspected the construction of the radiotherapy room at Sao San Tun Hospital in Taunggyi. The radiotherapy room is a single-story reinforced concrete building with a floor area of 95 feet × 52 feet, and the project is currently approximately 80% complete. During the inspection, officials from the building department reported on the project's construction progress, and the Chief Minister gave instructions on subsequent work and coordinated the necessary support. On the same day, the Chief Minister and his delegation also inspected the site for a planned five-story expansion building at the hospital and discussed related construction arrangements. Once completed, the radiotherapy room will be used to enhance the hospital's medical service capacity for radiotherapy-related care. ...

2026-08-31

Leo Cancer Care and GE HealthCare Announce Collaboration to Advance Upright Radiotherapy Workflow Integration

Leo Cancer Care recently announced a commercial collaboration with GE HealthCare, focusing on GE HealthCare's advanced imaging solutions and intelligent radiotherapy software, with plans to apply related technologies to Leo Cancer Care's future upright radiotherapy systems to streamline patient and data workflows from simulation to treatment delivery. Under the collaboration framework, the two parties will explore integration pathways between GE HealthCare's intelligent radiotherapy software iRT and Leo Cancer Care's future upright radiotherapy solutions. iRT is an AI-assisted software developed for radiotherapy settings, primarily used to connect information, workflows, and applications across different systems, helping healthcare institutions simplify complex processes, enable patients to enter radiotherapy more promptly, and reduce clinician burden.

2026-08-30

South Korea's SEC Joins National R&D Project for Active Dose Distribution Control Radiotherapy Equipment

South Korean electron beam source technology company SEC announced on August 25 that it has been selected as a joint research institution for the world's best active dose distribution control radiotherapy machine R&D project, and will participate in the development of core technologies related to next-generation radiotherapy equipment. The project is a newly established task under the Global Flagship Medical Device R&D Program of the South Korean government's medical device R&D fund, with a duration of 6 years and 6 months, starting from July this year and planned to continue until December 2032. The total project budget is 35.2 billion KRW, of which 28 billion KRW is government funding. Radexel serves as the lead institution, with SEC participating as a joint research institution. Other participating organizations include the Korea Atomic Energy Research Institute, Korea Testing Laboratory...

2026-08-25

Radexel leads South Korea's KRW 35.2 billion project to develop magnetically controlled radiotherapy equipment

South Korean medical device company Radexel announced on August 24 that it has been selected as the lead institution for a global flagship project, partnering with Asan Medical Center, the Korea Atomic Energy Research Institute (KAERI), and other organizations to develop next-generation radiotherapy equipment based on magnetic field control. The project is a national strategic R&D initiative jointly promoted by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, with a total investment of KRW 35.2 billion, including KRW 27.95 billion in government funding, over a seven-year period. Under the plan, the Radexel consortium will develop a Magnetically Controlled Radiotherapy (MPRT) system. This technology controls secondary...

2026-08-24

Construction of Radiotherapy and Radiosurgery Center Completed at Bulgaria's St. Ivan Rilski University Hospital

All construction and repair work for the new Radiotherapy and Radiosurgery Center at Bulgaria's St. Ivan Rilski University Hospital has been fully completed. According to the hospital, a latest-generation medical linear accelerator has been installed in the center, capable of sub-millimeter patient positioning accuracy. The equipment was delivered by the Ministry of Health under the National Recovery and Resilience Plan, as part of the investment project for the modernization of the national system for diagnosis and treatment of oncological diseases, funded by the European Commission's Recovery and Resilience Facility. The device is a TrueBeam-EDGE linear accelerator manufactured by Varian Medical Systems, equipped with BrainLab's ExactTrac Dynamic system, valued at 5.1 million...

2026-08-21

Second Radiotherapy Linear Accelerator Commissioned at Buchholz Hospital in Germany

The second medical linear accelerator for cancer radiotherapy at Buchholz Hospital in the North Heath region of Germany has been commissioned. The device was activated by the hospital's radiotherapy department under the direction of Chief Physician Dr. Günter Bohlen, marking a further enhancement of local oncological radiotherapy capabilities. The management of Buchholz Hospital and Winsen Hospital, Dr. Franziska von Brunnig (third from right) and Dr. Martin Meyer (first from right), together with Chief Physician Dr. Günter Bohlen (second from right) and the radiotherapy team, posed for a photo at the official commissioning ceremony of the second linear accelerator at Buchholz Hospital. Photo: Buchholz-Winsen Hospital. According to available information, Buchholz Hospital...

2026-08-20